DelveInsight launched a new report on Chemotherapy Induced Anemia Epidemiology Forecast to 2030
Some of the key facts of the report
The most common comorbid conditions before starting chemotherapy were hypertension (46.4%), diabetes (22.6%), and renal disease (11.2%). The most common regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (58.7%), followed by bendamustine with or without rituximab (11%).
The incidence of anaemia in cancer patients reported in literature varies significantly, ranging from 20% to 60% at the time of cancer diagnosis and reaching 60–90% during cancer treatments.
Request for sample pages:- https://www.delveinsight.com/sample-request/chemotherapy-induced-anemia-epidemiology-forecast
Scope of the Report
Reasons to buy
Table of contents
1. Key Insights
2. Executive Summary of Chemotherapy Induced Anemia
3. Chemotherapy Induced Anemia: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Chemotherapy Induced Anemia Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Chemotherapy Induced Anemia Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Chemotherapy Induced Anemia Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Chemotherapy Induced Anemia Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Chemotherapy Induced Anemia Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Chemotherapy Induced Anemia Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Chemotherapy Induced Anemia Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Chemotherapy Induced Anemia Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Chemotherapy Induced Anemia Treatment and Management
6.2. Chemotherapy Induced Anemia Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Related reports :-
Chemotherapy Induced Anemia- Market Insight, Epidemiology and Market Forecast -2030
DelveInsight’ s Chemotherapy Induced Anemia – Market Insights, Epidemiology and Market Forecast – 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.
Chemotherapy Induced Anemia – Pipeline Insights, 2020
Chemotherapy Induced Anemia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Chemotherapy Induced Anemia market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/